Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma

Oncotarget

Volumn 6, Issue 5, 2015, Pages 3098-3110

  Abdel Malek, Mohamed A Y ^a,b   Jagannathan, Sajjeev ^a   Malek, Ehsan ^a   Sayed, Douaa M ^b   Elgammal, Sahar A ^b   El Azeem, Hanan G Abd ^b   Thabet, Nabila M ^b   Driscoll, James J ^a,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Assiut University Faculty of Medicine   (Egypt)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Aggresome+Autophagosome pathway; Chemoresistance; GRP78; Myeloma; Proteasome

Indexed keywords

BORTEZOMIB; CELL PROTEIN; CELL RECEPTOR; GLUCOSE REGULATED PROTEIN 78; KDEL RECEPTOR; METFORMIN; PHENFORMIN; PROTEIN HSPA5; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN; MOLECULAR CHAPERONE GRP78; PROTEASOME INHIBITOR; RECEPTOR;

AGGRESOME; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOPHAGOSOME; CANCER RESISTANCE; CELL STRESS; CELL TRANSPORT; CELLULAR DISTRIBUTION; CHAPERONE-MEDIATED AUTOPHAGY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM; GENE MUTATION; GOLGI COMPLEX; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; UPREGULATION; ANTAGONISTS AND INHIBITORS; AUTOPHAGY; CELL ORGANELLE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; ENDOPLASMIC RETICULUM STRESS; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; BORTEZOMIB; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENDOPLASMIC RETICULUM STRESS; HEAT-SHOCK PROTEINS; HUMANS; METFORMIN; MULTIPLE MYELOMA; ORGANELLES; PROTEASOME INHIBITORS; RECEPTORS, PEPTIDE; SIGNAL TRANSDUCTION; TIME FACTORS; UP-REGULATION;

EID: 84923314909     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3075     Document Type: Article

References (63)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111: 2962-2972.
2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
3. Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011; 183: 25-35.
4. Reeder CB, Reece DE, Kukreti V, Mikhael JR, Chen C, Trudel S, Laumann K, Vohra H, Fonseca R, Bergsagel PL, Leis JF, Tiedemann R, Stewart AK. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. Br J Hematol 2014 167(4) 563-565.
5. http://seer.cancer.gov/statfacts/html/mulmy.html. NCI surveillance, epidemiology and end results program.
6. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J. Clin. Oncol. 2009; 27: 2758-65.
7. Mathis SE, Alberico A, Nande R, Neto W, Lawrence L, McAllister DR, Denvir J, Kimmey GA, Moqul M, Oakley G, Denning KL, Dougherty T, Valluri JV, Claudio PP. Chemo-Predictive Assay for Targeting Cancer Stem-Like Cells in Patients Affected by Brain Tumors. Plos One 2014; doi: 10.1371/pone.
8. Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG. From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol. 2007; 20: 797-816.
9. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013; 24: 289-304.
10. Orlowski R. Why proteasome inhibitors cannot ERADicate multiple myeloma.Cancer Cell 2013; 24:275-277.
11. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335-348.
12. Driscoll JJ, DeChowdhury R. Molecular Crosstalk between the proteasome, aggresomes and autophagy: Translational potential and clinical implications, Cancer Letters 2012; 325: 147-154.
13. Driscoll JJ, Woodle ES. Targeting the ubiquitin+proteasome system in solid tumors, Sem. in Hem. 2012; 49: 277-283.
14. Dick LR, Fleming PE. Building on bortezomib: secondgeneration proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010; 15:243-249.
15. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002;99:14374 -14379.
16. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530 - 1534.
17. Jagannathan S, Vad N, Vallabhapurapu Su, Vallabhapurapu Si, Anderson KC, Driscoll JJ. . MiR- 29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the anti-myeloma benefit of bortezomib Leukemia 2014 doi:10.1038/leu.2014.279.
18. Jagannathan S, Vad N, Malek E, Vallabhapurapu Su, Vallabhapurapu Si, Driscoll JJ. Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells. Oncotarget 2014; advanced online publication.
19. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao T-P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115: 727-738.
20. Kovacs PJ, Murphy S, Gaillard X, Zhao JT, Wu CV, Nicchitta M, Yoshida M, Toft DO, Pratt WB, Yao TP. HDAC6 regulates Hsp90 acetylation and chaperonedependent activation of glucocorticoid receptor. Mol. Cell 18 2005; 601-607.
21. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC, Anderson KC. Aggresome induction by bortezomib and a-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441-3449.
22. Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med. 2006; 6: 45-54.
23. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci.2001;26:504-510.
24. Hendershot LM. The ER function BiP is a master regulator of ER function. Mt Sinai J Med. 2004;71:289-297.
25. Ni M, Zhang Y, Lee AS. Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. The Biochem J. 2011; 434:181-188.
26. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8:519-529.
27. Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 2007;67: 3496-3499.
28. Gutiérrez NC, Ocio EM, de Las Rivas J, Maiso P, Delgado M, Fermiñán E, Arcos MJ, Sánchez ML, Hernández JM, San Miguel JF. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007; 21: 541-549.
29. Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol 2000; 2: 326-332.
30. Saito S, Furuno A, Sakurai J, Sakamoto A, Park HR, Shin- Ya K et al. Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Cancer Res. 2009; 69: 4225-4234.
31. Leclerc GM, Leclerc GJ, Kuznetsov JN, DeSalvo J, Barredo JC. Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts. Plos One 2013; 8:e74420. doi: 10.1371.
32. Woehlbier U, Hetz C. Modulating stress responses by the UPRosome: a matter of life and death. Trends Biochem Sci 2011; 36: 329-337.
33. Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008; 7: 1013-1030.
34. Li J, Ni M, Lee B, Barron E, Hinton DR, Lee AS. The unfolded protein response regulator GRP78/BiP is required for endoplasmic reticulum integrity and stress induced autophagy in mammalian cells. Cell Death Differ. 2008:15;1460-1471.
35. Ogata M, Hino S, Saito A, Morikawa K, Kondo S, Kanemoto S, et al. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol.2006; 26: 9220-9231.
36. Pollak M. Metformin and Other Biguanides in Oncology: Advancing the Research Agenda Cancer Prev Res 2010; 3:1060-1065.
37. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nature Rev Cancer 2008; 8:915-928.
38. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, Debernardis RJ, Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Research 2007; 67: 6745-6752.
39. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494: 256-260.
40. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011; 3196-3201.
41. Bae EJ, Cho MJ, Kim SG. Metformin prevents an adaptive increase in GSH and induces apoptosis under the conditions of GSH deficiency in H4IIE cells. J. Toxicol. Environ. Health 2007; 13: 1371-1380.
42. Rattan, R., Giri, S., Hartmann, L. C. & Shridhar, V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J. Cell Mol. Med. 2011; 15: 166-178.
43. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2012; 69: 7507-11.
44. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32:1620-5.
45. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev. Res. 2010; 3:1451-61.
46. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010; 9:1092-99.
47. Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo C, Lee JH, Shen CH, Bosenberg MW, McMahon M, Cantley LC, Zheng B. Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma. Proc Natl Acad Sci USA. 2013; 110: 18226-18231.
48. Miller RA, Birnbaum MJ. An energetic tale of AMPKindependent effects of metformin. J Clin Invest. 2010; 120: 2267-2270.
49. Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010; 11:390-401.
50. Wang, H.J. Chun, W. Wong, D.M. Spencer, M.J. Lenardo, Caspase-10 is an initiator caspase in death receptor signaling. Proc. Natl. Acad. Sci. USA, 2001; 98: 13884-13888.
51. Lamy L, Ngo VN, Emre NC, Shaffer AL 3rd, Yang Y, Tian E, Nair V, Kruhlak MJ, Zingone A, Landgren O, Staudt LM. Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell 2013; 23: 435-449.
52. Mijaljica D, Prescott M, Devenish RJ. Endoplasmic reticulum and Golgi complex: Contributions to, and turnover by, autophagy. Traffic 2006; 7: 1590-1595.
53. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen- induced lung tumorigenesis. Cancer Prev Res. 2010; 3: 1066-1076.
54. Quinn BJ, Kitagawa H, Memmott RM, Gillis JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends in Endocrin. and Metab. 2013; 24: 469-40.
55. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979; 16: 195-202.
56. Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, Cai J, Groshen S, Lieshovsky G, Skinner DG, Lee AS, Pinski J. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Human Pathology 2007; 38:1547-1552.
57. Uramoto H, Sugio K, Nakata S, Ono K, Yoshimastu T, Morita M, Yasumoto K. Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer 2005; 49: 55-62.
58. Wey S, Luo B, Tseng CC, Ni M, Zhou H, Fu Y, Bhojwani D, Carroll Wl, Lee AS. Inducible knockout of GRP78/ BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling. Blood 2012; 119: 817-825.
59. Zhang Y, Tseng CC, Tsai Y-L, Fu X, Schiff R, Lee AS. Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI (3,4, 5) P3 production. PloS one 2013; 10: e80071.
60. Liu R, Li X, Gao W, Zhou Y, Wey S, Mitra S, Krasnoperov V, Dong D, Liu S, Li D, Zhu G, Louie S, Conti PS, Li Z, Lee AS, Gill PS. Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis. Clinical Cancer Research 2013; 19: 6802-6811.
61. Cheong H, Lu C, Lindsten T, Thompson C. Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol. 2012; 10: 671-678.
62. Malek E, Jagannathan S, Driscoll JJ. Correlation of Long Non-Coding RNA Expression with Metastasis, Drug Resistance and Clinical Outcome in Cancer Oncotarget 2014; 5(18) 8027-8038.
63. Ahmad N, Haider S, Anaissie E, Driscoll JJ. MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia 2013; doi:10.1038/leu.2013.262.